Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1497TiP - REACTION – a phase Ib pilot study of nivolumab or nivolumab in combination with relatlimab after targeted radiation in patients with advanced esophagogastric cancer

Date

17 Sep 2020

Session

E-Poster Display

Topics

Immunotherapy

Tumour Site

Gastric Cancer

Presenters

Vincent Lam

Citation

Annals of Oncology (2020) 31 (suppl_4): S841-S873. 10.1016/annonc/annonc284

Authors

V.K. Lam1, R. Hales2, J.L. Feliciano3, K.R. Voong2, E. Shin1, K. Smith4, V. Anagnostou5, V. Velculescu6, E. Thompson7, C. Sears8, D. Pardoll9, H. Rodavia3, H. Schneider1, C. Hu10, A. Amjad11, P. Guerrieri11, B.A. Jobe11, A.H. Zaidi11, R.J. Kelly12

Author affiliations

  • 1 Medical Oncology, Johns Hopkins Sidney Kimmel Cancer Center, 21287 - Baltimore/US
  • 2 Radiation Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, 21224 - Baltimore/US
  • 3 Medical Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, 21224 - Baltimore/US
  • 4 Cancer Immunology, Johns Hopkins University, 21231 - Baltimore/US
  • 5 Medical Oncology, Johns Hopkins University, 21231 - Baltimore/US
  • 6 The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, MD 21287 - Baltimore/US
  • 7 Pathology, Johns Hopkins Sidney Kimmel Cancer Center, 21287 - Baltimore/US
  • 8 Infectious Disease, Johns Hopkins University, 21231 - Baltimore/US
  • 9 Cancer Immunology, Johns Hopkins Sidney Kimmel Cancer Center, 21287 - Baltimore/US
  • 10 Biostatistics And Bioinformatics, Johns Hopkins Sidney Kimmel Cancer Center, 21287 - Baltimore/US
  • 11 Esophageal Institute, Allegheny Health Network, 15224 - Pittsburgh/US
  • 12 Medical Oncology, The Charles A. Sammons Cancer Center at Baylor University Medical Center, 75246 - Dallas/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1497TiP

Background

Improving immunotherapy efficacy remains a large unmet need in esophagogastric cancer (EGC). Combining radiation therapy with immunotherapy represents a promising strategy, as radiation has been shown to augment T cell priming, trafficking, and effector responses within the tumor. Radiation can also enhance immunogenic cell death, potentially sensitizing otherwise non-inflamed tumors to anti-PD-1 therapy. We have shown that multiple checkpoints, including LAG-3, are upregulated in human samples pre and post chemo-radiation in esophageal cancer. In this study, we aim to investigate whether stereotactic body radiation therapy (SBRT) can enhance the effectiveness of anti-PD1 +/- anti-LAG-3 (relatlimab) immunotherapy by decreasing tumor bulk and altering the tumor microenvironment.

Trial design

This is a phase Ib single-arm, open-label pilot study (NCT03610711) in adult patients with recurrent or advanced EGC and are anti-PD-(L)1 therapy naive. This study aims to enroll 30 patients (15 patients in Arm A, then 15 patients in Arm B). Patients will receive SBRT 8Gy x 3 to one or more tumor lesions, followed by systemic therapy with nivolumab (Arm A) or nivolumab + relatlimab (Arm B) every 4 weeks until disease progression. A target lesion will be left un-radiated to enable correlative analyses. This lesion will biopsied prior to treatment and approximately 4 weeks later (after completion of radiation to the other metastatic sites and after 1 cycle of nivolumab +/- relatlimab). The primary objective of the study is to evaluate changes in infiltrating CD8+ T cell density pre and post treatment in a non-irradiated metastatic lesion. Key secondary and exploratory endpoints include safety, PFS, OS, and comprehensive correlative analyses of the tumor-specific T cell repertoire. Recruitment for this study began in March 2019, but was limited to oligometastatic EGC patients. Eligibility was recently expanded in March 2020 to allow polymetastatic patients. The study is actively enrolling and is funded by BMS.

Clinical trial identification

NCT03610711.

Editorial acknowledgement

Legal entity responsible for the study

Johns Hopkins.

Funding

Bristol-Myers Squibb.

Disclosure

V.K. Lam: Advisory/Consultancy: Takeda; Research grant/Funding (institution): BMS. C. Hu: Research grant/Funding (self): NCI; Research grant/Funding (self): RTOG; Advisory/Consultancy: Merck. R.J. Kelly: Advisory/Consultancy: BMS; Advisory/Consultancy: Novartis; Advisory/Consultancy: Eli Lilly; Advisory/Consultancy: Pieris Pharmaceuticals; Advisory/Consultancy: Astellas; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Takeda; Research grant/Funding (institution): BMS; Research grant/Funding (institution): Eli Lilly. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.